BridgeBio

BridgeBio
Management of Systemic AL Amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Systemic AL amyloidosis is a plasma cell dyscrasia with a characteristic clinical phenotype caused by multi-organ deposition of an amyloidogenic monoclonal protein…
Read more
May 10, 2015
Nutritional Counseling Improves Quality Of Life and Preserves Body Weight in Systemic Immunoglobulin Light-Chain (AL) Amyloidosis
Objective: Malnutrition is associated with mortality and impaired quality of life (QoL) in systemic immunoglobulin light-chain (AL) amyloidosis. The aim of this…
Read more
Oct 21, 2015
Recent Advances in the Management of AL Amyloidosis
Immunoglobulin light chain (AL) amyloidosis, the most common of the systemic amyloidosis, is characterized by the deposition of amyloid fibrils that derive from the…
Read more
Nov 19, 2015
The Patient's Perspective on the Symptom and Everyday Life Impact of AL Amyloidosis
Introduction: This study aimed to understand the symptomatic impact of amyloid light-chain (AL) amyloidosis from the patient's perspective. Methods: Four data…
Read more
Nov 09, 2015
Involvement of Oral Tissues by AL Amyloidosis: A Literature Review and Report of Eight New Cases
Objective: Amyloidosis is a term used to describe a group of diseases in which there is an extracellular deposition of amorphous fibrillar proteins known as amyloid…
Read more